Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 1
1990 3
1991 3
1992 5
1993 12
1994 11
1995 14
1996 25
1997 22
1998 43
1999 48
2000 60
2001 86
2002 105
2003 119
2004 115
2005 137
2006 144
2007 134
2008 180
2009 178
2010 182
2011 207
2012 245
2013 244
2014 253
2015 283
2016 253
2017 259
2018 183
2019 76
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

3,223 results
Results by year
Filters applied: . Clear all
Page 1
Sepsis and septic shock
Hotchkiss RS, et al. Nat Rev Dis Primers 2016 - Review. PMID 28117397 Free PMC article.
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.
Tokunaga R, et al. Cancer Treat Rev 2018 - Review. PMID 29207310 Free PMC article.
One of the mechanisms of resistance to checkpoint inhibitors may be chemokine signaling. The CXCL9, -10, -11/CXCR3 axis regulates immune cell migration, differentiation, and activation, leading to tumor suppression (paracrine axis). ...In this article, we summarize recent evidence regarding CXCL9, CXCL10, CXCL11/CXCR3 axis in the immune system and discuss their potential role in cancer treatment....
One of the mechanisms of resistance to checkpoint inhibitors may be chemokine signaling. The CXCL9, -10, -11/CXCR3 axis regulates imm …
Chemokine CXCL10 and Coronavirus-Induced Neurologic Disease.
Skinner D, et al. Viral Immunol 2019 - Review. PMID 30109979 Free PMC article.
Following microbial infection, there is often robust chemokine signaling elicited from infected cells, which contributes to both innate and adaptive immune responses that control growth of the invading pathogen. ...The T cell chemoattractant chemokine CXCL10 (interferon-inducible protein 10 kDa, IP-10) is prominently expressed in both stages of disease, and serves to attract activated T and B lymphocytes expressing CXC chemokine receptor 3 (CXCR3), the receptor for CXCL10. ...
Following microbial infection, there is often robust chemokine signaling elicited from infected cells, which contributes to both inna …
CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration.
Koper OM, et al. Adv Clin Exp Med 2018 - Review. PMID 29893515 Free article.
CXCL9, CXCL10, and CXCL11 lack glutamic acid-leucine-arginine (ELR), and are unique, because they are more closely related to each other than to any other chemokine. ...However, data in the literature concerning the evaluation of CXCL9, CXCL10, CXCL11, and their receptor with the use of the enzyme-linked immunosorbent assay (ELISA) method is limited....
CXCL9, CXCL10, and CXCL11 lack glutamic acid-leucine-arginine (ELR), and are unique, because they are more closely related to each ot …
Urinary CXCL10 Chemokine Is Associated With Alloimmune and Virus Compartment-Specific Renal Allograft Inflammation.
Ho J, et al. Transplantation 2018. PMID 28902772
BACKGROUND: Urinary CXC chemokine ligand 10 (CXCL10) is a promising biomarker for subclinical tubulointerstitial inflammation, but limited data exist regarding its correlation with (micro)vascular inflammation. ...Serum CXCL10 was not a useful marker for (micro)vascular inflammation....
BACKGROUND: Urinary CXC chemokine ligand 10 (CXCL10) is a promising biomarker for subclinical tubulointerstitial inflammation, …
Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity.
Karin N and Razon H. Cytokine 2018 - Review. PMID 29449068
CXCR3 is a chemokine receptor that is abundant on CD4+ T cells, CD8+ T cells and NK cells. It has three known ligands: CXCL9, CXCL10 and CXCL11. ...This makes CXCL10 a "key driver chemokine" and a valid target for therapy of autoimmune diseases such as Inflammatory Bowl's Disease, Multiple Sclerosis, Rheumatoid arthritis and others. ...
CXCR3 is a chemokine receptor that is abundant on CD4+ T cells, CD8+ T cells and NK cells. It has three known ligands: CXCL9, CXCL
STING-dependent sensing of self-DNA drives silica-induced lung inflammation
Benmerzoug S, et al. Nat Commun 2018. PMID 30523277 Free PMC article.
Patients with silicosis have increased circulating dsDNA and CXCL10 in sputum, and patients with fibrotic interstitial lung disease display STING activation and CXCL10 in the lung. ...
Patients with silicosis have increased circulating dsDNA and CXCL10 in sputum, and patients with fibrotic interstitial lung disease d …
Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise.
Trivedi PJ and Adams DH. J Crohns Colitis 2018 - Review. PMID 30137309 Free PMC article.
The principal targets for anti-chemokine therapy in inflammatory bowel disease (IBD) have been the receptors CCR9 and CXCR3 and their respective ligands CCL25 and CXCL10. ...In this article, we appraise the status of chemokine-directed therapy in IBD, review recent developments, and nominate future areas for therapeutic focus....
The principal targets for anti-chemokine therapy in inflammatory bowel disease (IBD) have been the receptors CCR9 and CXCR3 and their …
Elevation of the Chemokine Pair CXCL10/CXCR3 Initiates Sequential Glial Activation and Crosstalk During the Development of Bimodal Inflammatory Pain after Spinal Cord Ischemia Reperfusion.
Yu Q, et al. Cell Physiol Biochem 2018. PMID 30257241 Free article.
We investigated whether this chemokine pair participates in glial interactions during early-phase IR injury. METHODS: A rat model was induced by an 8-min occlusion of the aortic arch. ...Recombinant CXCL10 injection reversed the abovementioned effects. CONCLUSION: The results showed that CXCL10/CXCR3 are involved in bimodal inflammatory pain during early-phase IR injury. ...
We investigated whether this chemokine pair participates in glial interactions during early-phase IR injury. METHODS: A rat model was …
3,223 results
Jump to page
Feedback